Unlock this story — it’s free
Biovac and the South African Medical Research Council have launched clinical trials for a new oral cholera vaccine in Johannesburg. The project is the first end-to-end vaccine development in South Africa in decades. It comes as Africa faces rising cholera cases and limited global supplies.
What Happened?
Biovac and SAMRC opened Phase 1 trials from 17 November to 21 November 2025, moving the new oral vaccine from lab development to human testing. The vaccine arrives during a period of heightened cholera risk across the continent. Moreover, shortages of cholera doses worldwide have increased pressure on African health systems.
Researchers say the initiative strengthens the African Union’s 2030 goal for 60% local vaccine production. Global health partners are funding the program to accelerate progress. If trials succeed, officials expect roll-out in Africa by 2028.
Official Response
Scientists leading the trial called the launch a milestone for local innovation. Biovac executives noted that producing a vaccine end-to-end within South Africa boosts regional security.
A senior SAMRC researcher added:
“This program builds Africa’s capacity to respond faster during outbreaks.”
Government health authorities also welcomed the trial, emphasizing that local manufacturing shortens supply gaps during emergencies.
Community Impact
Health organisations say the project offers hope for communities hit hardest by repeated cholera waves. Furthermore, local production could reduce dependence on limited international stock.
For South Africans, the trial signals long-term resilience and better access to lifesaving vaccines.
